Search clinical trials for: LY2835219
Total 84 results
-
Eli Lilly and CompanyActive, not recruitingRelapsed Solid Tumor | Refractory Solid TumorUnited States, Canada, France, Australia, Belgium, Germany, Spain, Italy
-
Eli Lilly and CompanyTerminatedColorectal Cancer | Non-Small Cell Lung Cancer | Advanced Solid TumorUnited States, Australia
-
Eli Lilly and CompanyCompletedPancreatic Ductal AdenocarcinomaUnited States, Spain, Taiwan, France, Belgium, Australia, Israel, United Kingdom
-
Eli Lilly and CompanyWithdrawnMetastatic Breast CancerUnited States, Taiwan, Italy, Austria, Germany, Puerto Rico, Belgium, Argentina, Brazil
-
Eli Lilly and CompanyCompletedHER-2 Positive Breast Cancer | Hormone Receptor Positive Breast CancerSpain, United States, Korea, Republic of, Belgium, France, Germany, Italy, Australia, Argentina, Canada, United Kingdom, Mexico, Brazil, Greece
-
Eli Lilly and CompanyCompletedSoft Tissue Sarcoma | Breast Cancer | Solid Tumor | Cholangiocarcinoma | Colon CancerUnited States, France, Spain, Denmark
-
Eli Lilly and CompanyActive, not recruitingUrogenital Neoplasms | Prostatic Neoplasms | Neoplasm Metastasis | Enzyme Inhibitors | Antineoplastic Agents | Hormones | Physiological Effects of Drugs | Antineoplastic Agents, Hormonal | Androgens | Hormones, Hormone Substitutes, and Hormone Antagonists | Abiraterone Acetate | Steroid Synthesis Inhibitors | Cytochrome... and other conditionsChina, Canada, France, United States, Australia, Czechia, Hungary, Spain, Germany, Japan, Taiwan, Netherlands, Mexico, Belgium, Korea, Republic of, Turkey, Argentina, Romania, United Kingdom, Italy, Israel, Brazil, Poland, Greece
-
Eli Lilly and CompanyActive, not recruitingBreast CancerCanada, Germany, Australia, Japan, United States, Taiwan, Belgium, New Zealand, Italy, Israel, Spain, France, Netherlands, Mexico, Turkey, United Kingdom, Korea, Republic of, Austria, Puerto Rico, Sweden, Russian Federation, Greece, Slovaki...
-
Eli Lilly and CompanyActive, not recruitingBreast CancerChina, India, South Africa, Brazil
-
Eli Lilly and CompanyActive, not recruitingMetastatic Breast CancerSpain, Taiwan, United States, Italy, Czechia, Germany, Belgium, Turkey, Brazil, Russian Federation, Argentina, Austria, France, Mexico
-
Eli Lilly and CompanyRecruitingBreast Neoplasms | Neoplasm MetastasisJapan, United States, China, Czechia, Belgium, Brazil, Germany, Netherlands, Russian Federation, Ukraine, Taiwan, France, Korea, Republic of, Italy, Spain, Australia, Turkey, India, Argentina, Greece, Austria, Mexico
-
Eli Lilly and CompanyMerck Sharp & Dohme LLCActive, not recruitingBreast Cancer | Non Small Cell Lung CancerUnited States, Spain, France, Belgium, Italy, Taiwan, Turkey
-
Eli Lilly and CompanyCompletedBreast Neoplasms | Neoplasm MetastasisIndia
-
Eli Lilly and CompanyCompletedBreast Cancer | Early-Stage Breast Carcinoma | Hormone Receptor Positive TumorUnited States, Canada, Korea, Republic of, Italy, Austria, Belgium, Germany, Netherlands, Spain, Taiwan
-
Eli Lilly and CompanyActive, not recruitingProstate CancerUnited States, China, Australia, Japan, Spain, Korea, Republic of, Netherlands, Denmark, Germany, France, Romania
-
Eli Lilly and CompanyCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAnatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Breast CarcinomaUnited States
-
Eli Lilly and CompanyMerck Sharp & Dohme LLCCompletedCarcinoma, Non-small Cell LungUnited States, Spain
-
Vadim S KoshkinEli Lilly and Company; Prostate Cancer FoundationActive, not recruitingCastration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Castration-resistant Prostate Cancer | Metastatic Prostate Adenocarcinoma | Metastatic Castration-resistant Prostate CarcinomaUnited States
-
University of LeicesterEli Lilly and Company; GlaxoSmithKline; Merck Sharp & Dohme LLC; Roche Pharma AG; British Lung Foundation and other collaboratorsActive, not recruitingMesothelioma, MalignantUnited Kingdom
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyActive, not recruitingBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Endometrial CancerUnited States, Spain, France, Belgium, Taiwan, Australia, Korea, Republic of, Japan
-
Eli Lilly and CompanyTerminatedMetastatic Breast CancerUnited States, Puerto Rico
-
National Cancer Institute (NCI)Active, not recruitingAnatomic Stage IV Breast Cancer AJCC v8 | Recurrent Breast Carcinoma | Metastatic Breast Carcinoma | Metastatic HER2-Negative Breast Carcinoma | Metastatic Hormone Receptor-Positive Breast CarcinomaUnited States
-
Eli Lilly and CompanyLoxo Oncology, Inc.RecruitingBreast CancerUnited States, Spain, Korea, Republic of, China, France, Germany, Japan, Belgium, Italy, Australia, United Kingdom, Canada, Singapore
-
Dana-Farber Cancer InstituteEli Lilly and CompanyNot yet recruitingEndometrial Cancer | Recurrent Endometrial Cancer | TP53United States
-
Eli Lilly and CompanyRecruitingAdolescent | Neoplasms | ChildUnited States, Spain, United Kingdom, Australia, Italy, Japan, Belgium, France, Germany
-
Eli Lilly and CompanyCompletedColorectal Cancer | Metastatic Melanoma | Advanced Cancer | Metastatic Non-small Cell Lung CancerUnited States, Japan, Australia, France
-
Eli Lilly and CompanyCompletedNeoplasm MetastasisUnited States
-
Eli Lilly and CompanyCompletedNon-Hodgkin's Lymphoma | Metastatic Cancer | Malignant Mesothelioma | Metastatic Breast Cancer | Non-small Cell Lung Cancer | Advanced CancerUnited States, Puerto Rico, Italy
-
Eli Lilly and CompanyActive, not recruitingBreast NeoplasmsUnited States
-
University of WashingtonBreast Cancer Research FoundationNot yet recruitingAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic HER2-Negative Breast Carcinoma | Metastatic Hormone Receptor-Positive Breast Carcinoma | Locally Advanced Unresectable HER2-Negative Breast Carcinoma | Locally Advanced Unresectable Hormone Receptor-Positive...United States
-
Multiple Myeloma Research ConsortiumEli Lilly and Company; GlaxoSmithKline; AbbVie; Takeda; Genentech, Inc.; Celgene Corporation and other collaboratorsRecruitingRelapsed Refractory Multiple MyelomaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityTerminatedPrimary Myelofibrosis | Anemia | Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic... and other conditionsUnited States